Related Experiment Video
Updated: Feb 11, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
S Siena1, A Sartore-Bianchi1, S Marsoni2
1Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan.
Abstract:
Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic colorectal cancer (CRC) tumors is driven by amplification or mutation of HER2. This paper reviews the role of HER2 amplification as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 testing in this tumor type. While the role of HER2 as a biomarker for prognosis in CRC remains uncertain, its relevance as a therapeutic target has been established. Indeed, independent studies documented substantial clinical benefit in patients treated with biomarker-driven HER2-targeted therapies, with an impact on response rates and duration of response that compared favorably with immunotherapy and other examples of precision oncology. HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of metastatic CRC patients.
Insights
Human epidermal growth factor receptor 2 (HER2) drives a subset of metastatic colorectal cancer (CRC). HER2-targeted therapies show significant clinical benefit, offering a new precision oncology approach for these patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Human epidermal growth factor receptor 2 (HER2) is a known oncogenic driver and therapeutic target in breast and gastric cancers.
- Previous research identified HER2 amplification or mutation in approximately 5% of metastatic colorectal cancer (CRC) tumors.
Purpose of the Study:
- To review the role of HER2 amplification in metastatic colorectal cancer (CRC).
- To discuss HER2 as an oncogenic driver, prognostic/predictive biomarker, and therapeutic target in CRC.
- To consider the specifics of HER2 testing in CRC.
Main Methods:
- Review of functional and genomic analyses of patient-derived xenografts.
- Analysis of existing literature on HER2 in CRC.
- Evaluation of clinical trial data for HER2-targeted therapies in CRC.
Main Results:
- HER2 amplification is an established therapeutic target in a subset of metastatic CRC.
- HER2-targeted therapies demonstrate substantial clinical benefit, improving response rates and duration compared to other treatments.
- The prognostic role of HER2 in CRC remains uncertain, but its predictive value for targeted therapy is clear.
Conclusions:
- HER2-targeted therapies represent a significant advancement in precision oncology for metastatic CRC.
- These strategies have the potential to alter the treatment landscape for a relevant subgroup of CRC patients.
- Accurate HER2 testing is crucial for identifying patients who will benefit from targeted treatments.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
09:16Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
Related Concept Videos
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Targeted Cancer Therapies
There are several types of targeted therapies against...
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity